StreetInsider.com News Articles

Form 4 Theravance Biopharma, For: Jul 06 Filed by: Samaha Eli

Wed, 08 Jul 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260708/26747686.html

Form 4 Theravance Biopharma, For: Jul 06 Filed by: Samaha Eli

Wed, 08 Jul 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260708/26747686.html

H.C. Wainwright Downgrades Theravance Biopharma (TBPH) to Neutral

Tue, 07 Jul 2026 07:37:18 -0400

H.C. Wainwright analyst Douglas Tsao downgraded Theravance Biopharma (NASDAQ: TBPH) from Buy to Neutral.

For an analyst ratings summary and ratings history on Theravance Biopharma click here. For more ratings news on Theravance Biopharma click here.

Shares of Theravance Biopharma closed at $17.00 yesterday.

H.C. Wainwright Downgrades Theravance Biopharma (TBPH) to Neutral

Tue, 07 Jul 2026 07:37:18 -0400

H.C. Wainwright analyst Douglas Tsao downgraded Theravance Biopharma (NASDAQ: TBPH) from Buy to Neutral.

For an analyst ratings summary and ratings history on Theravance Biopharma click here. For more ratings news on Theravance Biopharma click here.

Shares of Theravance Biopharma closed at $17.00 yesterday.

Form 4 Theravance Biopharma, For: Jun 29 Filed by: Samaha Eli

Wed, 01 Jul 2026 19:34:00 -0400

si-local-file:///var/storage/secattach/20260701/26722586.html

Form 4 Theravance Biopharma, For: Jun 29 Filed by: Samaha Eli

Wed, 01 Jul 2026 19:34:00 -0400

si-local-file:///var/storage/secattach/20260701/26722586.html

BTIG Downgrades Theravance Biopharma (TBPH) to Neutral

Mon, 29 Jun 2026 09:20:33 -0400

BTIG analyst Julian Harrison downgraded Theravance Biopharma (NASDAQ: TBPH) from Buy to Neutral.

The analyst comments "Zymeworks (ZYME, Not Rated) has agreed to acquire TBPH for $17/sh, which is a 22% premium to TBPH's closing price on the day Phase 3 CYPRESS results were shared and a 10% premium to the volume-weighted average share price since this day (March 3, 2026). We do not anticipate any materially higher offers, and we expect this deal to close in 2H26, reflecting a culmination of TBPH's strategic review announced in March 2026. We believe ZYME makes sense as an acquirer given Yupelri's addition to

BTIG Downgrades Theravance Biopharma (TBPH) to Neutral

Mon, 29 Jun 2026 09:20:33 -0400

BTIG analyst Julian Harrison downgraded Theravance Biopharma (NASDAQ: TBPH) from Buy to Neutral.

BTIG Downgrades Theravance Biopharma (TBPH) to Neutral

Mon, 29 Jun 2026 09:20:33 -0400

BTIG analyst Julian Harrison downgraded Theravance Biopharma (NASDAQ: TBPH) from Buy to Neutral.

BTIG Downgrades Theravance Biopharma (TBPH) to Neutral

Mon, 29 Jun 2026 09:20:33 -0400

BTIG analyst Julian Harrison downgraded Theravance Biopharma (NASDAQ: TBPH) from Buy to Neutral.

Jones Trading Downgrades Theravance Biopharma (TBPH) to Hold

Mon, 29 Jun 2026 08:34:22 -0400

Jones Trading analyst Debanjana Chatterjee downgraded Theravance Biopharma (NASDAQ: TBPH) from Buy to Hold.

For an analyst ratings summary and ratings history on Theravance Biopharma click here. For more ratings news on Theravance Biopharma click here.

Shares of Theravance Biopharma closed at $17.63 yesterday.

Jones Trading Downgrades Theravance Biopharma (TBPH) to Hold

Mon, 29 Jun 2026 08:34:22 -0400

Jones Trading analyst Debanjana Chatterjee downgraded Theravance Biopharma (NASDAQ: TBPH) from Buy to Hold.

For an analyst ratings summary and ratings history on Theravance Biopharma click here. For more ratings news on Theravance Biopharma click here.

Shares of Theravance Biopharma closed at $17.63 yesterday.

Form DEFA14A Theravance Biopharma,

Mon, 29 Jun 2026 06:32:00 -0400

si-local-file:///var/storage/secattach/20260629/26701650.html

Form DEFA14A Theravance Biopharma,

Mon, 29 Jun 2026 06:32:00 -0400

si-local-file:///var/storage/secattach/20260629/26701650.html

Form 8-K Theravance Biopharma, For: Jun 28

Mon, 29 Jun 2026 06:31:00 -0400

si-local-file:///var/storage/secattach/20260629/26701647.html

Form 8-K Theravance Biopharma, For: Jun 28

Mon, 29 Jun 2026 06:31:00 -0400

si-local-file:///var/storage/secattach/20260629/26701647.html

Zymeworks to acquire Theravance Biopharma for $17 per share

Mon, 29 Jun 2026 06:01:46 -0400

Zymeworks Inc. has agreed to acquire Theravance Biopharma, Inc. (NASDAQ: TBPH) for $17.00 per share in cash, representing an equity value of approximately $929 million, according to a press release issued June 29, 2026.

Theravance Biopharma shareholders will also receive a contingent value right (CVR) entitling them to 80% of net proceeds from any future license, divestiture, or other monetization of ampreloxetine over the next ten years. Zymeworks will retain the remaining 20% of such proceeds.